Hypera Stock

Hypera Debt/EBITDA

The Total Debt to EBITDA Ratio of Hypera (HYPE3.SA) as of Aug 4, 2026 is 3.96. In the previous year, Total Debt to EBITDA Ratio was 4.54 — a change of -12.83% (lower).

Debt/EBITDA

3.96

YoY

-12.83%

Last updated:

Total Debt to EBITDA Ratio of Hypera is 2026 3.96 . Total Debt to EBITDA Ratio of Hypera was 2025 4.54 . It decreases by -12.83% lower compared to the previous year.
Access this data via the Eulerpool API

Hypera Stock analysis

What does Hypera do? Hypera SA is a Brazilian pharmaceutical company founded in 2001, specializing in the development, production, and distribution of drugs, generics, medical devices, and cosmetic products primarily for the Brazilian healthcare industry. Hypera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hypera stock

Total Debt to EBITDA Ratio of Hypera is 3.96 in 2026.

Total Debt to EBITDA Ratio of Hypera changed from 4.54 to 3.96, representing a -12.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Hypera since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Hypera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Hypera

All Key Metrics — Hypera